Back to search

University of Thessaly (UTH)

Οι πολυμορφισμοί των programmed cell death-1 (PD-1) rs 11568821, interleukin -28B (IL28B) rs12979860 και patatin-like phospholipase domain- containing protein 3 (PNPLA3) rs 738409 στην αυτοάνοση ηπατίτιδα

Abstract

dc:description

Autoimmune hepatitis (AIH) is a relatively rare chronic liver disease. To date, no single pathophysiological hypothesis can comprehensively explain the entire spectrum of the disease. A unifying theory suggests that the initial triggering event, involving antigen selection, is influenced by human leukocyte antigen (HLA) II predisposition. Subsequently, polymorphisms in other immune regulatory and cytokine-producing genes including epigenetics may promote and perpetuate immune reactivity, loss of self-tolerance and inflammatory responses.The PD1 protein is involved in T-cell regulation and cytokine production favoring self-tolerance. A single nucleotide polymorphism rs11568821 (PD1.3) has been associated with several other autoimmune diseases. Data regarding PD1.3 in autoimmune liver disease are scarce. The IL28B rs12979860 polymorphism has been associated with the lipid profile, insulin resistance and the presence of hepatic steatosis in patients with HCV infection. It is also related with hepatic inflammation in both HCV and metabolic associated steatotic liver disease (MASLD). To the best of our knowledge the role of the IL28B rs12979860 in inflammatory response andliver damage has not been studied in autoimmune liver diseases. The PNPLA3 rs738409 (I148M) polymorphism has been associated with hepatic steatosis and progressive fibrosis in several chronic liver diseases apart MASLD. Limited available data support its role as a disease modifier in autoimmune liver disease as well. The aim of the present study was to investigate the prevalence and clinical significance of the above-mentioned polymorphisms in patients with AIH in order to extent current knowledge regarding how genetic background affectsthe disease. We also aimed at identifying possible new biomarkers that could aid in clinical decision-making and patient follow-up. Two hundred consecutive patients with well-established AIH followed in our Center were included in the study. One hundred age- and sex-matched healthy subjects served as controls. PD1.3 and IL28B rs12979860 genotyping was performed with in-house end-point allelic discrimination real time PCR using specific custom-made primers and minor groove binder probes. Results were confirmed by PCR - restriction fragment length polymorphism (RFLP) and direct sequencing, respectively. PNPLA3 I148M genotyping was also performed with end-point allelic discrimination RT- PCR with predetermined primers and minor groove binder probes designed for the specific polymorphism.PD1.3 was detected in 36/200 (18%) AIH patients and 28/100 (28%) healthy controls. No correlation was found with disease susceptibility, clinical phenotype or prognosis. Interestingly, patients not baring the polymorphism (GG homozygotes) suffered more frequently from concurrent extra-hepatic autoimmune diseases (p = 0.001), but without predisposition for a particulardisease. The distribution of IL28B rs12979860 genotypes in AIH patients [CC 79/200 (39.5%), TT 36/200 (18%), CT 85/200 (42.5%)] was similar with the control group [CC 42/100 (42%), TT 16/100 (16%), CT 42/100 (42%)]. CC patients had higher low-density lipoprotein (LDL) cholesterol levels (p=0.027), but no differences were found regarding the presence of steatosis, steatohepatitis or hepatic inflammation and fibrosis. The effect of IL28B rs12979860 on treatment response was significant, with CC patients achieving higher rates of complete biochemical remission at 12 months (88% vs. 69.2%, p=0.005) and higher treatment withdrawal rates (36.1% vs. 19.2%, p=0.020). The PNPLA3 rs738409 polymorphism was present in 95/200 (47.5%) patients with AIH and 47/100 (47%) healthy controls. Patients baring the I148M were more likely to present with decompensation at the time of diagnosis (6.3% vs. 1%, p=0.039) and tended to require longer immunosuppressive treatment before reaching remission (p=0.07). On Kaplan Meier analysis homozygosity for the G allele was associated with reduced survival free of decompensation (p=0.006), cirrhotic adverse events (decompensation, hepatocellular carcinoma) (p=0.001) and liver-related death or liver transplantation (p=0.011). In conclusion, the PD1.3 polymorphism does not seem to contribute to AIH susceptibility and disease course. Contrary, IL28B rs12979860 could pose as a novel biomarker for AIH, aiding clinicians in decision-making regarding treatment withdrawal in patients baring the “responder” genotype. Lastly, PNPLA3 rs738409 could be used as a surrogate marker to help identify AIH patients at increased risk for disease progression, allowing for personalized medical care.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Azariadis, Kalliopi
  • Αζαριάδη, Καλλιόπη

Subjects

dc:subject × 25

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61518

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Azariadis, Kalliopi; Αζαριάδη, Καλλιόπη. Οι πολυμορφισμοί των programmed cell death-1 (PD-1) rs 11568821, interleukin -28B (IL28B) rs12979860 και patatin-like phospholipase domain- containing protein 3 (PNPLA3) rs 738409 στην αυτοάνοση ηπατίτιδα. University of Thessaly (UTH), 2026. http://hdl.handle.net/10442/hedi/61518